Evrard Emma, Motamed Cyrus, Pagès Arnaud, Bordenave Lauriane
Department of Anesthesiology, Gustave Roussy, 94805 Villejuif, France.
Faculty of Medicine, University of Paris-Saclay, 94270 Le Kremlin Bicêtre, France.
J Clin Med. 2023 Jan 23;12(3):904. doi: 10.3390/jcm12030904.
Opioid sparing is one of the new challenges in anesthesia and perioperative medicine. Opioid reduced anesthesia (ORA) is part of this approach, and it consists of a multimodal analgesia-associating non-opioid analgesic regional anesthesia to reduce intraoperative opioid requirements. Major cervicofacial oncologic surgery could specifically benefit from ORA, since it is known to generate intense and prolonged postoperative pain, with a high risk of pulmonary complications.
This is a retrospective case-controlled study of 172 patients with major cervicofacial oncologic surgery. Group ORA (dexmedetomidine and lidocaine), = 86, was compared to patients treated with standard opioid based anesthesia, Group control, = 86. The main endpoint was to study perioperative opioid consumption and postoperative pain scores, and the secondary endpoint was to observe opioid related side effects.
The ORA group received 6.2 ± 3.1 mg morphine titration at the end of surgery, while the control group received 10.1 ± 3.7 mg < 0.0001; there was no significant difference in post-operative analgesia requirements and pain scores between the groups. Intraoperatively, the ORA protocol yielded bradycardia in 4 persons, while in the control group, only 2 persons had bradycardia necessitating intervention, < 0.05. Postoperatively, episodes of hypoxemia (50%) and the need for additional pressure-assisted ventilation (6%), was significantly different in the ORA group than in the control group (70% and 19%), < 0.05. There was no difference between the two groups for the incidence of nausea and vomiting, ileus, or postoperative delirium.
ORA was not associated with a decrease in postoperative pain and opioid requirement, but possibly reduced the incidence of hypoxemia and the use of additional pressure-assisted ventilation, although we cannot rule out confounding factors. The possible benefits of ORA remain to be demonstrated by prospective studies.
减少阿片类药物用量是麻醉和围手术期医学面临的新挑战之一。减少阿片类药物的麻醉(ORA)是这种方法的一部分,它包括多模式镇痛联合非阿片类镇痛区域麻醉,以减少术中对阿片类药物的需求。重大颌面肿瘤手术可能特别受益于ORA,因为已知该手术会产生强烈且持久的术后疼痛,并有较高的肺部并发症风险。
这是一项对172例重大颌面肿瘤手术患者进行的回顾性病例对照研究。将ORA组(右美托咪定和利多卡因),n = 86,与接受标准阿片类药物麻醉治疗的患者(对照组,n = 86)进行比较。主要终点是研究围手术期阿片类药物的消耗量和术后疼痛评分,次要终点是观察阿片类药物相关的副作用。
ORA组在手术结束时接受了6.2±3.1mg吗啡滴定,而对照组接受了10.1±3.7mg(P<0.0001);两组之间术后镇痛需求和疼痛评分无显著差异。术中,ORA方案使4人出现心动过缓,而在对照组中,只有2人因心动过缓需要干预(P<0.05)。术后,ORA组低氧血症发作(50%)和需要额外压力辅助通气的情况(6%)与对照组(70%和l9%)相比有显著差异(P<0.05)。两组在恶心、呕吐、肠梗阻或术后谵妄的发生率方面没有差异。
ORA与术后疼痛和阿片类药物需求的减少无关,但可能降低了低氧血症的发生率和额外压力辅助通气的使用,尽管我们不能排除混杂因素。ORA的潜在益处仍有待前瞻性研究证实。